[{"id":"b2d0e16f-9f16-4b18-afd1-1b771c949f14","acronym":"","url":"https://clinicaltrials.gov/study/NCT05955105","created_at":"2024-05-21T20:33:37.710Z","updated_at":"2024-07-02T16:35:02.295Z","phase":"Phase 1/2","brief_title":"A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies","source_id_and_acronym":"NCT05955105","lead_sponsor":"Innolake Biopharm","biomarkers":" PD-L1 • TMB • MSI • CD8 • CD68","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • TMB • MSI • CD8 • CD68"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • ILB-2109"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 07/25/2023","start_date":" 07/25/2023","primary_txt":" Primary completion: 01/25/2026","primary_completion_date":" 01/25/2026","study_txt":" Completion: 07/24/2026","study_completion_date":" 07/24/2026","last_update_posted":"2024-05-21"}]